-

Butterfly Network to Participate at Oppenheimer 35th Annual Healthcare MedTech & Services Virtual Conference on March 18, 2025

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”) a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced that it will participate at the Virtual Oppenheimer 35th Annual Healthcare MedTech & Services Conference on March 18, 2025. Joseph DeVivo, President, Chief Executive Officer & Chairman and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will host one-on-one investor meetings and take part in a Fireside Chat at 11:20am EDT.

A webcast of the Fireside Chat will be available in the Events & Presentations section of the Butterfly investor website.

To schedule a one-on-one meeting with Mr. DeVivo and Ms. Getz, please reach out to your Oppenheimer representative.

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore’s Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly’s innovations have also been recognized by Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, among other achievements.

Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.

Contacts

Butterfly Investors:
Heather Getz
Chief Financial and Operations Officers, Butterfly
investors@butterflynetwork.com
or
Steve Halper
LifeSci Advisors (IR Representative)
646-876-6455
shalper@lifesciadvisors.com

Butterfly Network, Inc.

NYSE:BFLY

Release Versions
$Cashtags

Contacts

Butterfly Investors:
Heather Getz
Chief Financial and Operations Officers, Butterfly
investors@butterflynetwork.com
or
Steve Halper
LifeSci Advisors (IR Representative)
646-876-6455
shalper@lifesciadvisors.com

Social Media Profiles
More News From Butterfly Network, Inc.

Butterfly Network to Report First Quarter 2026 Financial Results on April 30, 2026

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, announced that it will report first quarter 2026 financial results on Thursday, April 30, 2026, at 8:00 am ET. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and John Doherty, Executive Vice President and Chief Financial Officer, will host a conference call and webcast...

Butterfly Network Secures First FDA Clearance for Blind Sweep Ultrasound AI Tool, Marking a Major Stride for Women’s Health

BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (“Butterfly,” “the Company”) (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for a fully automated Gestational Age (GA) Tool integrated into its handheld ultrasound solution. This marks the first FDA-cleared blind-sweep ultrasound AI tool for estimating gestational age....

Butterfly Network Appoints David Horsley as Senior Vice President, Innovation – Butterfly Embedded™

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, programmable cloud software and AI, today announced the appointment of David Horsley, Ph.D. as Senior Vice President of Innovation – Butterfly Embedded™ to scale its Ultrasound-on-Chip™ co-development and licensing initiative. In this role, Dr. Horsley will lead strategy and go-to-market for Butterfly Embedded, overseeing new product...
Back to Newsroom